Figure S1. Effects of downregulation of miR-92a-3p on HUVEC proliferation and migration. HUVEC were transfected with miR-92a inhibitor (miR-92a-3p-i) or NC inhibitor (NC-i) for 48 h. (A) Cell proliferation was determined by EdU incorporation assay and (B) quantified by counting the percentage of EdU-positive cells in total cells. **P<0.01 vs. NC-i; n=3. (C) Cell migration was assessed by scratch wound assay and (D) quantified by measuring scratch closure area. ***P<0.001 vs. NC-I; n=3. Magnification, x100. HUVECs, human umbilical vein endothelial cells.



Figure S2. Potential target genes of miR-92a-3p in HUVECs. HUVECs were transfected with miR-92a inhibitor (miR-92a-3p-i) or NC inhibitor (NC-Supplementary_Data i) for 48 h and the mRNA expression profiles were determined by mRNA sequencing (n=2). Green circles represent the differentially expressed (DE) genes. Red circles represent the putative targets of miR-92a-3p predicted by the RNAhybrid program. Up, upregulated. The 21 genes in the gray box were shared by the upregulated 91 genes screened by mRNA sequencing and 4,167 predicted targets. HUVECs, human umbilical vein endothelial cells.



Table SI. Differentially expressed miRNAs in HUVECs treated with $Exo^{-H_2O_2}$ and Exo^{-Con}.

miRNA	Fold change ($Exo^{-H_2O_2}$ vs. Exo^{-Con})	P-value
hsa-miR-92a-3p	0.7	0.04
hsa-miR-7851-3p	<0.1	0.01
hsa-miR-548az-5p	0.3	0.04
hsa-miR-5000-3p	<0.1	0.04
hsa-miR-4727-3p	<0.1	0.04
novel_292	0.1	0.04
hsa-miR-9-5p	2.4	0.04
hsa-miR-6724-5p	3.1	0.02
hsa-miR-579-5p	2.1	0.04
hsa-miR-556-5p	2.6	0.02
hsa-miR-3938	3.2	0.01
hsa-miR-3691-5p	2.9	0.03

miRNAs with a P-value <0.05 are shown. $Exo^{-H_2O_2}$, exosomes from H_2O_2-stimulated HUVECs; Exo^{-Con}, exosomes from HUVECs without stimulation; HUVECs, human umbilical vein endothelial cells.